Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zubinor-PG
- Development stage
- Unknown
- Lead developer
- Elliott Labs
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Zubinor-PG is a fixed-dose combination sustained-release tablet developed and marketed by Elliott Labs. It contains pregabalin (75 mg), nortriptyline (10 mg), and methylcobalamin (1500 mcg). This combination is primarily indicated for the management of neuropathic pain, including diabetic peripheral neuropathy and post-herpetic neuralgia. Pregabalin acts as a gabapentinoid that binds to the alpha-2-delta subunits of voltage-gated calcium channels, reducing the release of excitatory neurotransmitters. Nortriptyline is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin, thereby enhancing descending inhibitory pain pathways. Methylcobalamin, an active form of vitamin B12, acts as a cofactor for methionine synthase, promoting myelin sheath synthesis and supporting nerve regeneration. Together, these components provide synergistic relief for chronic neuropathic pain.
- Brand names
- Zubinor PGZubinor-PGZubinor-PG Tablet SR
- Other names
- methylcobalamin + nortriptyline + pregabalin
02
Targets
SERT (Sodium-dependent serotonin transporter)α2δ (Voltage-gated calcium channel alpha-2-delta subunit)NET (Norepinephrine Transporter)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)MTR (Methionine synthase)
Beyond the preview
Go deeper on Zubinor-PG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zubinor-PG.